Assessment of anthracycline-induced cardiotoxicity with electrocardiography

Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males) treated with 2–6 cycles of anthracycline-based chem...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2009
Автори: Horacek, J.M., Jakl, M., Horackova, J., Pudil, R., Jebavy, L., Maly, J.
Формат: Стаття
Мова:English
Опубліковано: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2009
Назва видання:Experimental Oncology
Теми:
Онлайн доступ:http://dspace.nbuv.gov.ua/handle/123456789/136213
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Digital Library of Periodicals of National Academy of Sciences of Ukraine
Цитувати:Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ.

Репозитарії

Digital Library of Periodicals of National Academy of Sciences of Ukraine
id irk-123456789-136213
record_format dspace
spelling irk-123456789-1362132018-06-17T03:08:51Z Assessment of anthracycline-induced cardiotoxicity with electrocardiography Horacek, J.M. Jakl, M. Horackova, J. Pudil, R. Jebavy, L. Maly, J. Short communications Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males) treated with 2–6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline (before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 ± 117.5 mg/m2 ) and circa 6 months after CT. Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated. Results: During treatment and follow-up, we found a statistical significant QTc interval prolongation — 414.7 ± 16.0 ms (before CT), 419.6 ± 21.6 ms(after first CT), 428.0 ± 16.2 ms(after last CT) and 430.1 ± 18.4 ms(6 months after CT). Significant QTc interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated with oncology treatment were present in 9 patients within 6 months after CT. Conclusion: Anthracycline treatment is associated with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and non-invasive screening method indicating LV dysfunction after anthracycline treatment. 2009 Article Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ. 1812-9269 http://dspace.nbuv.gov.ua/handle/123456789/136213 en Experimental Oncology Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
institution Digital Library of Periodicals of National Academy of Sciences of Ukraine
collection DSpace DC
language English
topic Short communications
Short communications
spellingShingle Short communications
Short communications
Horacek, J.M.
Jakl, M.
Horackova, J.
Pudil, R.
Jebavy, L.
Maly, J.
Assessment of anthracycline-induced cardiotoxicity with electrocardiography
Experimental Oncology
description Aim: Monitoring of anthracycline-induced cardiotoxicity with electrocardiography (ECG) and comparing ECG changes with findings on echocardiography (ECHO). Methods: A total of 26 adult acute leukemia patients (mean age 46.2 ± 12.4 years, 15 males) treated with 2–6 cycles of anthracycline-based chemotherapy (CT) were studied. Cardiac evaluation was performed at the baseline (before CT), after first CT, after last CT (cumulative anthracycline dose 464.3 ± 117.5 mg/m2 ) and circa 6 months after CT. Time ECG parameters, QRS voltage, presence of repolarization changes, arrhythmias and other abnormalities were evaluated. Results: During treatment and follow-up, we found a statistical significant QTc interval prolongation — 414.7 ± 16.0 ms (before CT), 419.6 ± 21.6 ms(after first CT), 428.0 ± 16.2 ms(after last CT) and 430.1 ± 18.4 ms(6 months after CT). Significant QTc interval prolongation (> 450 ms) occurred in 3 patients after first CT, in 4 patients after last CT and in 5 patients within 6 months after CT. Significant total QRS voltage lowering in the limb leads (> 1.0 mV versus before CT) occurred in 3 patients after first CT, in 5 patients after last CT and in 6 patients within 6 months after CT. We found a statistically significant correlation between decreased QRS voltage, QTc interval prolongation and left ventricular (LV) dysfunction on ECHO. Repolarization changes associated with oncology treatment were present in 9 patients within 6 months after CT. Conclusion: Anthracycline treatment is associated with changes in electrical activity of the myocardium. Prolonged QTc interval represents a risk for development of malignant ventricular arrhythmias. Decreased QRS voltage and prolonged QTc interval after anthracycline treatment could correlate with LV dysfunction on ECHO. Further studies will be needed to prove whether these ECG changes could serve as an accessible and non-invasive screening method indicating LV dysfunction after anthracycline treatment.
format Article
author Horacek, J.M.
Jakl, M.
Horackova, J.
Pudil, R.
Jebavy, L.
Maly, J.
author_facet Horacek, J.M.
Jakl, M.
Horackova, J.
Pudil, R.
Jebavy, L.
Maly, J.
author_sort Horacek, J.M.
title Assessment of anthracycline-induced cardiotoxicity with electrocardiography
title_short Assessment of anthracycline-induced cardiotoxicity with electrocardiography
title_full Assessment of anthracycline-induced cardiotoxicity with electrocardiography
title_fullStr Assessment of anthracycline-induced cardiotoxicity with electrocardiography
title_full_unstemmed Assessment of anthracycline-induced cardiotoxicity with electrocardiography
title_sort assessment of anthracycline-induced cardiotoxicity with electrocardiography
publisher Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України
publishDate 2009
topic_facet Short communications
url http://dspace.nbuv.gov.ua/handle/123456789/136213
citation_txt Assessment of anthracycline-induced cardiotoxicity with electrocardiography / J.M. Horacek, M. Jakl, J. Horackova, R. Pudil, L. Jebavy, J. Maly // Experimental Oncology. — 2009. — Т. 31, № 2. — С. 115–117. — Бібліогр.: 15 назв. — англ.
series Experimental Oncology
work_keys_str_mv AT horacekjm assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
AT jaklm assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
AT horackovaj assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
AT pudilr assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
AT jebavyl assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
AT malyj assessmentofanthracyclineinducedcardiotoxicitywithelectrocardiography
first_indexed 2023-10-18T21:13:15Z
last_indexed 2023-10-18T21:13:15Z
_version_ 1796152235553456128